MARKET

VERU

VERU

VERU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.900
-0.310
-5.95%
After Hours: 4.900 0 0.00% 19:54 01/21 EST
OPEN
5.08
PREV CLOSE
5.21
HIGH
5.17
LOW
4.880
VOLUME
2.49M
TURNOVER
--
52 WEEK HIGH
24.57
52 WEEK LOW
4.880
MARKET CAP
391.28M
P/E (TTM)
48.09
1D
5D
1M
3M
1Y
5Y
Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug
The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.
Zacks · 01/12 16:39
9 Consumer Staples Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 01/11 17:40
PSTI, NES and VORB among mid-day movers
Gainers: Splash Beverage Group (NYSE:SBEV) +37%. Virgin Orbit Holdings (NASDAQ:VORB) +26%. TSR (NASDAQ:TSRI) +27%. Accolade (NASDAQ:ACCD) +26%. BARK (NYSE:BARK) +25%. Veru (NASDAQ:VERU) +22%. Nutriband (NASDAQ:NTRB) +22%. Nuverra Environmental Solutions (N...
Seekingalpha · 01/11 17:39
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.
Benzinga · 01/11 17:01
Veru rebounds on late recognition of Fast Track tag for breast cancer drug
Veru (VERU +23.2%) shares have recovered after five straight sessions of losses on above-average volume as the market reacts to the Fast Track Designation granted by the FDA to the
Seekingalpha · 01/11 17:01
OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 01/11 14:15
Why Jim Cramer Likes Grab Holdings
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: VERU)'s Enobosarm was granted fast track designation for the treatment of AR+ ER+ HER2- metastatic breast cancer by the FDA.
Benzinga · 01/11 14:13
MFGP, LAC and VIR among pre market gainers
Splash Beverage (NYSE:SBEV) +58% receives authorization for TapouT in Walmart Stores across Florida metropolitan areas. TSR TSRI +38% on FQ2 results. Black Diamond Therapeutics BDTX +17%  wins FDA nod to start clinical trial for
Seekingalpha · 01/11 13:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VERU. Analyze the recent business situations of VERU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VERU stock price target is 24.40 with a high estimate of 29.00 and a low estimate of 21.00.
High29.00
Average24.40
Low21.00
Current 4.900
EPS
Actual
Estimate
-0.040.040.120.21
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 132
Institutional Holdings: 24.62M
% Owned: 30.83%
Shares Outstanding: 79.85M
TypeInstitutionsShares
Increased
36
2.45M
New
20
704.42K
Decreased
35
2.27M
Sold Out
22
969.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Personal Products
+0.02%
Personal & Household Products & Services
+0.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mitchell Steiner
Vice Chairman/Director
Harry Fisch
Chief Financial Officer/Chief Administrative Officer
Michele Greco
Chief Scientific Officer
K. Barnette
Independent Director
Mario Eisenberger
Independent Director
Grace Hyun
Independent Director
Lucy Lu
Independent Director
Michael Rankowitz
Declaration Date
Dividend Per Share
Ex-Div Date
03/24/2014
Dividend USD 0.07
04/28/2014
12/16/2013
Dividend USD 0.07
01/27/2014
10/03/2013
Dividend USD 0.07
10/28/2013
07/15/2013
Dividend USD 0.07
07/29/2013
03/27/2013
Dividend USD 0.07
04/29/2013
01/03/2013
Dividend USD 0.06
01/28/2013
10/04/2012
Dividend USD 0.06
10/29/2012
07/13/2012
Dividend USD 0.06
07/30/2012
03/27/2012
Dividend USD 0.06
04/30/2012
01/04/2012
Dividend USD 0.05
01/30/2012
10/06/2011
Dividend USD 0.05
10/31/2011
07/14/2011
Dividend USD 0.05
07/29/2011
04/11/2011
Dividend USD 0.05
04/29/2011
01/14/2011
Dividend USD 0.05
01/27/2011
10/08/2010
Dividend USD 0.05
11/01/2010
07/22/2010
Dividend USD 0.05
08/02/2010
--
Dividend USD 0.05
04/21/2010
01/14/2010
Dividend USD 0.05
01/27/2010
About VERU
Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing novel medicines for the management of prostate and breast cancers. It operates through two segments: Sexual Health Business and Research and Development. The Sexual Health Business segment includes a drug candidate, TADFYN, for the treatment of benign prostatic hyperplasia (BPH) and a commercial product, the FC2 Female Condom/ Internal Condom (FC2). The Research and Development segment includes multiple products and management evaluating each product in its portfolio of products. The Company's prostate cancer drug pipeline includes Sabizabulin (VERU-111), VERU-100 and Zuclomiphene citrate. Sabizabulin (VERU-111) is an oral chemical entity that targets and inhibits microtubules to disrupt transport of the androgen receptor into the nucleus (androgen receptor transport disruptor). VERU-100 for androgen deprivation therapy (ADT) of advanced prostate cancer.

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.